Advertisement

Clinical Immunotherapeutics

, Volume 2, Issue 6, pp 430–442 | Cite as

Immunopathogenesis and Management of Myasthenia Gravis

  • Aashit K. Shah
Practical Therapeutics
  • 4 Downloads

Summary

Myasthenia gravis is a well known and well understood autoimmune disorder. Weakness in patients with myasthenia gravis is caused by the autoimmune destruction of acetylcholine receptors at the neuromuscular junction. The autoimmune mechanisms are not simple, and involve T cells, B cells and their interactions.

Tools for the diagnosis of myasthenia gravis include: (a) clinical evaluation; (b) determination of the serum anti-acetylcholine receptor antibody; and (c) electro-diagnostic methods such as single fibre electromyography and repetitive nerve stimulation. Treatment involves symptomatic treatment with acetylcholinesterase inhibitors and both conventional (corticosteroids and other immunosuppressants) and nonconventional (plasmapheresis, intravenous immunoglobulin and thymectomy) immunomodulating therapies.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Strauss AJL, Seigal BC, Hsu KC, et al. Immunofluorescence demonstration of a muscle binding complement fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol 1960; 105: 184Google Scholar
  2. 2.
    Osserman KE. Myasthenia gravis. New York: Grune and Stratton, 1958: 78–79, 86–87Google Scholar
  3. 3.
    Hokkanen E. Epidemiology of myasthenia gravis in Finland. J Neurol Sci 1969; 9: 463–78PubMedCrossRefGoogle Scholar
  4. 4.
    Kurtzke J. Epidemiology of myasthenia gravis. Adv Neurol 1978; 19: 545–64PubMedGoogle Scholar
  5. 5.
    Engel AG. Myasthenia gravis and myasthenic syndromes. Ann Neurol 1984; 16: 519–34PubMedCrossRefGoogle Scholar
  6. 6.
    Toyka KV, Drachman DB, Griffin DE, et al. Myasthenia gravis: study of humoral immune mechanisms by transfer to mice. N Engl J Med 1977; 296: 125PubMedCrossRefGoogle Scholar
  7. 7.
    Engel AG, Lambert EH, Howard PM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultra-structural and light microscopic localization and electrophysiological correlations. Mayo Clin Proc 1977; 52: 267PubMedGoogle Scholar
  8. 8.
    Patric J, Lindstrom JM. Autoimmune response to acetylcholine receptor. Science 1973; 180: 871CrossRefGoogle Scholar
  9. 9.
    Wekerle H. The thymus in myasthenia gravis. Ann NY Acad Sci 1993; 681: 47–55PubMedCrossRefGoogle Scholar
  10. 10.
    Tsuchiya N, Williams RC. Molecular mimicry — hypothesis or reality? West J Med 1992; 157: 133–8PubMedGoogle Scholar
  11. 11.
    Oosterhuis HJGH. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989; 52: 1121–7PubMedCrossRefGoogle Scholar
  12. 12.
    Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Ann NY Acad Sci 1981; 377: 652–69PubMedCrossRefGoogle Scholar
  13. 13.
    Oosterhuis HJGH. Long term effects of treatment in 374 patients with myasthenia gravis. Monogr Allergy 1988; 25: 75–85PubMedGoogle Scholar
  14. 14.
    Cohen MS, Younger D. Aspects of natural history of myasthenia gravis: crisis and death. Ann NY Acad Sci 1981; 377: 670–7PubMedCrossRefGoogle Scholar
  15. 15.
    Engel AG. Acquired autoimmune myasthenia gravis. In: Engel AG, Banker BQ, editors. Myology: basic and clinical. New York: McGraw-Hill, 1986: 1925–54Google Scholar
  16. 16.
    Limburg PC, The TH, Hummel-Tappel E, et al. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1: relation to clinical parameters in 250 patients. J Neurol Sci 1983; 58: 357–70PubMedCrossRefGoogle Scholar
  17. 17.
    Drosos AA, Christou L, Galanopoulu V, et al. D-Penicillamine-induced myasthenia gravis: clinical, serological and genetic findings. Clin Exp Rheumatol 1993; 11: 387–91PubMedGoogle Scholar
  18. 18.
    Tindall RSA. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol 1981; 10: 437–47PubMedCrossRefGoogle Scholar
  19. 19.
    Oosterhuis HJGH, Limburg PC, Hummel-Tappel E, et al. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2: clinical and serological follow-up of individual patients. J Neurol Sci 1983; 58: 371–85PubMedCrossRefGoogle Scholar
  20. 20.
    Biesecker G, Koffler D. Immunology of myasthenia gravis. Hum Pathol 1983; 14(5): 419–23PubMedCrossRefGoogle Scholar
  21. 21.
    Oh SJ. Single fiber electromyography in various diseases. In: Oh SJ, editor. Electromyography: neuromuscular transmission studies. Baltimore: Williams and Wilkins, 1988: 254–91Google Scholar
  22. 22.
    Sanders DB, Phillips LH. Single fiber electromyography: an AAEE workshop. Rochester, Minnesota: American Association of Electromyography and Electrodiagnosis, 1984Google Scholar
  23. 23.
    Seybold ME, Drachman DB. Gradual increasing dose of prednisone in myasthenia gravis: reducing hazards of treatment. N Engl J Med 1974; 290: 81–4PubMedCrossRefGoogle Scholar
  24. 24.
    Pascuzzi R, Coslettt HB, Johns TR. Long term treatment of myasthenia gravis: report of 116 cases. Ann Neurol 1984; 15: 291–8PubMedCrossRefGoogle Scholar
  25. 25.
    Sghirlanzoni A, Plechetti D, Mantegazza R, et al. Myasthenia gravis: prolonged treatment with steroids. Neurology 1984; 34: 170–4PubMedCrossRefGoogle Scholar
  26. 26.
    Sutton DM, Nair RC, Rock G, et al. Complications of plasma exchange. Transfusion 1989; 29(2): 124–7PubMedCrossRefGoogle Scholar
  27. 27.
    Wirguin I, Brenner T, Shinar E, et al. Citrate-induced impairment of neuromuscular transmission in human and experimental autoimmune myasthenia gravis. Ann Neurol 1990; 27: 328–30PubMedCrossRefGoogle Scholar
  28. 28.
    Arsura EL, Bick A, Brunner NG, et al. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986; 146: 1365–8PubMedCrossRefGoogle Scholar
  29. 29.
    Cosi V, Lombardi M, Piccolo G, et al. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 1991; 84: 81–4PubMedCrossRefGoogle Scholar
  30. 30.
    Steg RE, Leftkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994; 44: 1180PubMedCrossRefGoogle Scholar
  31. 31.
    Shah AK, Lisak RP. Neurologic complications of immunomodulating therapy. In: Bruyn G, Vinken PJ, editors. Handbook of clinical neurology — intoxications of the nervous system. Part 2. Amsterdam: Elsevier. In pressGoogle Scholar
  32. 32.
    Fonseca V, Harvard CW. Long term treatment of myasthenia gravis with azathioprine. Postgrad Med J 1990; 66: 102–5PubMedCrossRefGoogle Scholar
  33. 33.
    Witte AS, Cornblath DR, Perry GJ, et al. Azathioprine in treatment of myasthenia gravis. Ann Neurol 1984; 15: 602–5PubMedCrossRefGoogle Scholar
  34. 34.
    Mattel G. Immunosuppressive drugs: azathioprine in treatment of myasthenia gravis. Ann NY Acad Sci 1987; 505: 588–94CrossRefGoogle Scholar
  35. 35.
    Perez MC, Buot WL, Mercado-Danguilan C, et al. Stable remission in myasthenia gravis. Neurology 1981; 31: 32–7PubMedCrossRefGoogle Scholar
  36. 36.
    Schalke B, Kappos L, Dommasch D, et al. Cyclosporine treatment of myasthenia gravis: initial results of double-blind trial of cyclosporine A versus azathioprine. Ann NY Acad Sci 1987; 505: 872–5CrossRefGoogle Scholar
  37. 37.
    Tindall R, Rollins J, Phillips JT, et al. Preliminary results of double blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987; 316: 719–24PubMedCrossRefGoogle Scholar
  38. 38.
    Neuberg-Hansen R, Gjerstad L. Myasthenia gravis treated with cyclosporine. Acta Neurol Scand 1988; 77: 307–13CrossRefGoogle Scholar
  39. 39.
    Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953–1040PubMedCrossRefGoogle Scholar
  40. 40.
    Blalock A, Mason MF, Morgan HF, et al. Myasthenia gravis and tumors of the thymic region. Report of a case in which the tumor was removed. Ann Surg 1939; 110: 544PubMedCrossRefGoogle Scholar
  41. 41.
    Blalock A. Thymectomy in the treatment of myasthenia gravis. Report of twenty cases. J Thorac Surg 1944; 13: 316Google Scholar
  42. 42.
    Robinson CL. The role of surgery of the thymus for myasthenia gravis. Ann R Coll Surg Engl 1983; 65: 145–51PubMedGoogle Scholar
  43. 43.
    Ahlberg R, Yi Q, Pirskanen R, et al. Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T cell autoreactivity. Neurology 1994; 44: 1732–7PubMedCrossRefGoogle Scholar
  44. 44.
    Drachman DB, Mcintosh KR, Reim J, et al. Strategies for treatment of myasthenia gravis. Ann NY Acad Sci 1993; 681: 515–28PubMedCrossRefGoogle Scholar
  45. 45.
    Plauche WC. Myasthenia gravis in mothers and their newborn. Clin Obstet Gynecol 1991; 34: 82–99PubMedCrossRefGoogle Scholar
  46. 46.
    Brenner T, Beyth Y, Abramsky O. Inhibitory effect of alpha fetoprotein on the binding of myasthenia gravis antibody to acetylcholine receptor. Proc Natl Acad Sci USA 1977; 77: 3635CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Aashit K. Shah
    • 1
  1. 1.Department of NeurologyWayne State University, 6E University Health CenterDetroitUSA

Personalised recommendations